Ipamorelin Mechanism of Action
Part of the full Ipamorelin guide - a selective growth-hormone secretagogue reference compound, identity-verified with a COA on every vial.
In brief
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) characterized in laboratory models as a selective agonist of the growth-hormone-secretagogue receptor 1a (GHS-R1a), the ghrelin receptor expressed on anterior-pituitary somatotrophs. This spoke describes the receptor-coupling and signal-transduction events reported for this peptide in model systems. All statements are mechanistic and in-vitro / receptor-signaling in scope; no human, therapeutic, or outcome claim is implied.
The detail
A closer look
01
Receptor target: GHS-R1a
The defining molecular target documented for ipamorelin is GHS-R1a, the ghrelin receptor (sourceHint: Raun et al. 1998). GHS-R1a is a class-A (rhodopsin-like) G-protein-coupled receptor expressed on anterior-pituitary somatotrophs in the model systems studied. Ipamorelin is described in the entry data as a selective agonist of this receptor, meaning it engages the same receptor as the endogenous ligand ghrelin rather than acting through the separate GHRH-receptor axis. Because it is a peptide agonist of a defined GPCR, the relevant readouts in receptor-signaling assays are binding occupancy at GHS-R1a and the downstream second-messenger cascade that occupancy triggers.
02
Signal transduction: Gq/11 to PLC to IP3 and calcium
In receptor-signaling terms, agonist binding couples GHS-R1a to the Gq/11 family of heterotrimeric G proteins. Per the entry, activated Gq/11 stimulates phospholipase C (PLC), which hydrolyzes membrane phosphatidylinositol substrate to raise inositol-trisphosphate (IP3) and intracellular calcium. The rise in intracellular Ca2+ is the proximal trigger that, in somatotroph models, drives exocytosis of stored growth-hormone vesicles. The causal chain documented in the data is therefore: agonist binding at GHS-R1a, Gq/11 coupling, PLC activation, IP3 generation, intracellular calcium elevation, and calcium-dependent vesicular release in the somatotroph model. This is a classic Gq-PLC-calcium GPCR cascade as applied to a pituitary cell model.
03
Selectivity as the signature property
The entry frames selectivity as ipamorelin's defining research feature. Across the preclinical models referenced, the peptide is reported to evoke growth-hormone release without the proportional rise in ACTH, cortisol, or prolactin that was seen with earlier-generation secretagogues. In signal-transduction language this means the GHS-R1a-coupled somatotroph response is engaged while the corticotroph (ACTH/cortisol axis) and lactotroph (prolactin) outputs are not proportionally co-activated, distinguishing it from less-selective comparator compounds in the same assay families.
04
Structure-driven receptor interaction
The data attributes this selectivity to two non-coded residues in the sequence: aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal). These non-proteinogenic residues are described as shaping the receptor interaction in a way that favors the selective GHS-R1a-mediated somatotroph response. The presence of D-amino-acid and alpha,alpha-disubstituted residues in the pentapeptide is the structural basis the entry assigns to the receptor-selectivity profile, linking the molecule's primary structure directly to its signaling fingerprint.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Ipamorelin is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.